Form 4 for OCUL OCULAR THERAPEUTIX, INC

Accepted 2022-02-07 00:00:00 ET · period of report 2022-02-03 · accession 0001104659-22-012919 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-02-07	2022-02-03	OCUL	Goldstein Michael H.	Pres, CMO, Ophthalmology	A - Grant	$0.00	+63.3K	313.3K	+25%	$0
D	2022-02-07	2022-02-03	OCUL	Goldstein Michael H.	Pres, CMO, Ophthalmology	A - Grant	$0.00	+190.0K	190.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-02-03	A	A	63,333	$0.00	313,335	D	—	—	(F1) On February 3, 2022, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service to the Company, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. (F2) Includes (i) 63,333 shares of common stock of the Company underlying unvested RSUs and (ii) 2 shares of the Company's common stock acquired under the 2014 Ocular Therapuetix, Inc. Employee Stock Purchase Plan on December 31, 2021.
2	Derivative	Stock Option (Right to Buy)	2022-02-03	A	A	190,000	$0.00	190,000	D	$5.27 · — to 2032-02-02	190,000 Common Stock	(F3) Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.